×

Endocyte Announces Presentations at the 252nd American Chemical Society National Meeting & Exposition

WEST LAFAYETTE, Ind., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that five posters will be presented by Endocyte scientists at the 252nd American Chemical Society (ACS) National Meeting & Exposition being held in Philadelphia, August 21-25, 2016.

“Endocyte’s versatile technology platform for developing SMDCs toward receptor-specific targeting will be highlighted at the national ACS meeting,” said Iontcho Vlahov, Ph.D., vice president of discovery chemistry. “The focus of our presentations is on novel chemistries for targeted therapies of cancer, including the concept of proPBDs and their hybrids with DNA minor groove binders, targeting of duocarmycins and auristatins, and the introduction of somatostatin-receptor-targeting conjugates. We will also discuss our continued advancement in the design of novel linkers for SMDCs of the super-potent drug tubulysin."

Presentations are as follows:

Abstract #: MEDI 35
Title: “Utility of monomethyl auristatin (MMA) analogs as payloads for targeted therapies of cancer: Design and synthesis of MMAE and MMAF folate conjugates
When: Sunday, Aug. 21, 2016, from 7 - 9 p.m. EDT
Session ID: General Poster Session
Location: Hall G - Pennsylvania Convention Center

Abstract #: MEDI 36
Title: “Design and synthesis of seco-Duocarmycin analogs as warheads in small molecule drug conjugates (SMDCs) for targeted cancer therapies
When: Sunday, Aug. 21, 2016, from 7 - 9 p.m. EDT
Session ID: General Poster Session
Location: Hall G - Pennsylvania Convention Center

Abstract #: MEDI 37
Title: “Novel Targets for Small Molecule Drug Conjugates: Design and Synthesis of Somatostatin Analogs as targeting ligands and their Conjugates with Cytotoxic Warheads
When: Sunday, Aug. 21, 2016, from 7 – 9 p.m. EDT
Session ID: General Poster Session
Location: Hall G - Pennsylvania Convention Center

Abstract #: MEDI 38
Title: “Design and synthesis of Small Molecule Drug Conjugates: additional structural motifs
When: Sunday, Aug. 21, 2016, from 7 – 9 p.m. EDT
Session ID: General Poster Session
Location: Hall G - Pennsylvania Convention Center

Abstract #: MEDI 39
Title: “Design, synthesis and early evaluation of hybrids of DNA minor groove binders and DNA-alkylating agents as warheads for small molecule drug conjugates (SMDCs) for targeted cancer therapies
When: Sunday, Aug. 21, 2016, from 7 – 9 p.m. EDT
Session ID: General Poster Session
Location: Hall G - Pennsylvania Convention Center

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.

Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com

Source:Endocyte, inc